Intellia Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
HAELO data by mid-2026 with a planned BLA submission in H2 2026 , while scaling commercial, payer and manufacturing readiness for a potential one-time HAE launch. The in vivo ATTR program (nex-z) was placed on clinical hold after liver enzyme events; the FDA lifted the hold for MAGNITUDE-2 (polyneuropathy) with added liver monitoring, steroid guidance and tighter screening, but the cardiomyopathy study MAGNITUDE remains on hold pending further review. Intellia had $605.1 million in cash at Dec. 31, 2025—projected to fund operations into the second half of 2027—and reported higher collaboration revenue with a reduced Q4 net loss of $95.8 million Interested in Intellia Therapeutics, Inc.? Here are five stocks we like better. Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook Intellia Therapeutics (NASDAQ:NTLA) management used its fourth-quarter and full-year 2025 earnings call to highlight progress across its two lead in vivo CRISPR gene-editing programs—lonvo-z
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory [Seeking Alpha]Seeking Alpha
- This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/26/26 - Beat
NTLA
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- NTLA's page on the SEC website